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Background: Peripheral arterial disease (PAD) is a marker of advanced atherosclerosis with 
an elevated risk of cardiovascular mortality and morbidity. Although intensive risk reduction 
therapy is critical in reducing the adverse cardiovascular outcomes in patients with PAD, the 
awareness of this information among all physicians is felt to be low. Given the role of family 
physicians (FP), general internists (GI), cardiologists (C), and vascular surgeons (VS) in treating 
patients with PAD, we sought to determine their perceptions and knowledge of risk reduction 
therapy in these patients.
Methods and results: We conducted a cross-sectional self-administered survey of 84 physi-
cians who work at a major teaching hospital. FP, GI, C, and VS represent 39%, 33%, 16%, and 
12% of the surveyed physicians, respectively. The recommended targets of LDL-cholesterol, 
blood glucose and blood pressure in PAD patients were known to 37.3%, 94.1% and 35.3% of 
physicians, respectively. The majority of physicians reported to screen for risk factors in PAD. 
Although 86.3% of physicians would recommend antiplatelets therapy in PAD, only 17.6% 
would recommend angiotensin converting enzyme (ACE) inhibitors; 25.5% would recommend 
nicotine replacement therapy for smokers and 62.7% would recommend statins. Compared to 
other specialties, cardiologists had the lowest threshold, whereas GI had the highest threshold 
for initiating antiplatelets and statins for patients with PAD.
Conclusion: The perceptions towards risk reduction in PAD identify glaring knowledge and 
action gaps. Effective strategies to encourage health professionals to use risk reduction therapy 
are needed.
Keywords: peripheral arterial disease, risk reduction, atherosclerosis
Introduction
Peripheral arterial disease (PAD) is an atherosclerotic disease that affects lower 
extremities. The risk factors for PAD are the same as those for atherosclerosis in general 
and include male sex, advanced age, cigarette smoking, hypertension, diabetes, and 
hyperlipidaemia (Fowkes et al 1992).
PAD is a marker of advanced atherosclerosis with an elevated risk of cardiovascular 
mortality and morbidity. Patients with PAD have a 4 fold increased risk of myocardial 
infarction (Criqui et al 1992) and a 2–3-fold increased risk of stroke (Wilterdink and 
Easton 1992) compared to persons without PAD. Furthermore, the risk of cardiovas-
cular mortality and morbidity in patients with PAD is comparable to that in patients 
with coronary artery disease (CAD) (CAPRIE Steering Committee 1996).
Reducing the adverse cardiovascular outcomes of atherosclerosis through risk factor 
identiﬁ  cation and modiﬁ  cation has been an active area of research over the past few Vascular Health and Risk Management 2007:3(6) 1020
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decades. Since PAD is a marker of advanced atherosclerosis 
with an elevated risk of cardiovascular mortality and mor-
bidity, intensive risk reduction therapy is critical in these 
patients. Risk reduction therapy such as smoking cessation, 
blood sugar control, blood pressure control, antiplatelets, 
statin, and angiotensin converting enzyme (ACE) inhibitors 
are proven therapy in reducing the risk of cardiovascular 
mortality and morbidity in PAD patients (Stratton et al 2000; 
Yusuf et al 2000; Antithrombotic Trialists’ Collaboration 
2002; Heart Protection Collaborative Group 2002; Lu and 
Creager 2004; Willigendael et al 2004). These results have 
led several expert committees in recommending their use 
patients with PAD (Abramson et al 2005; Hirsch et al 2006; 
Smith et al 2006).
Although the adverse outcomes in patients with PAD 
are well documented, the awareness of this information 
among all physicians is felt to be low (Hirsch et al 2004). 
The knowledge and implementation of atherosclerotic risk 
factors reduction in PAD patients have been shown to be 
suboptimal among general practitioners, internal medicine 
specialists, cardiologists, and vascular surgeons in the United 
States, Canada and the United Kingdom (Hirsch et al 2001; 
McDermott et al 2002; Cassar, Belch et al 2003; Cassar, 
Coull et al 2003; Al Omran et al 2006).
The knowledge and implementation of risk factors reduc-
tion in patients with PAD among physicians in Saudi Arabia 
are not known and given the central role of physicians prac-
ticing in academic institutes in disseminating the standard of 
care in treating various diseases, this study was performed 
to assess the knowledge of the recommended target levels 
for blood pressure, blood glucose and LDL-cholesterol and 
knowledge and attitude towards risk reduction therapy in 
patients with PAD among physicians practicing in a major 
teaching hospital in Saudi Arabia.
Methods
A self-administered questionnaire was mailed to all 
family physicians, general internists, cardiologists and 
vascular surgeons working at King Khalid University 
Hospital (KKUH) in Riyadh, Saudi Arabia in March 2006. 
KKUH is the major teaching hospital for the college of 
medicine, King Saud University; which is the oldest and 
largest medical school in Saudi Arabia. The questionnaire 
was based on a previously published questionnaire with 
some modiﬁ  cations (Al Omran et al 2006). The question-
naire was anonymous and physicians were consented 
before participation. This study was approved by KKUH 
Ethics Review Board.
The survey contained multiple-choice questions 
(Appendix). The questions requested information from 
participants regarding their demographics (age, gender, 
specialty, board certiﬁ  cation status, years of experience), 
their knowledge about target levels of blood pressure, 
LDL-cholesterol, and blood glucose in patients with PAD, 
in addition to their attitudes toward patient counseling about 
cardiovascular risk reduction; comfort with recommending 
and instituting risk reduction therapy (smoking cessation, 
antiplatelets; statin; ACE inhibitors; and antihypertensive 
medications), factors that inﬂ  uence adequate risk reduction 
therapy delivery in PAD patients, proportion of patients 
with PAD who have their vascular risk factors evaluated 
systematically by the participants, and their self-assessment 
of PAD risk reduction knowledge.
All survey results are expressed as percentages. The num-
ber of respondents who completed each question provided the 
denominator for proportions of responses. The prespeciﬁ  ed 
subgroups for analysis were specialty type (family physicians 
versus general internists versus cardiologists versus vascular 
surgeons). Chi-square tests were used to compare proportions 
between different subgroups. All p-values reported were two 
tailed, and were considered signiﬁ  cant at the 0.05 level.
Results
Fifty one of the 84 surveyed physicians at KKUH completed 
the survey, representing a response rate of 60.7%. Family phy-
sicians, general internists, cardiologists and vascular surgeons 
represent 39%, 33%, 16%, and 12% of the surveyed physi-
cians, respectively. The results are depicted in Tables 1–4.
Physicians’ characteristics
Two third of participated physicians are board certiﬁ  ed in 
their specialties. Almost half of the respondents were practic-
ing for more than 10 years (Table 1).
Physicians’ knowledge and attitude
The knowledge of the surveyed participants for the recom-
mended targets of LDL-cholesterol and blood pressure was 
low, on the other hand their knowledge for the recommended 
target level of blood glucose was high (Table 2). Only 
21.6% knew that ACE inhibitor can be initiated in PAD 
patients irrespective of the blood pressure status, as an anti-
atherosclerotic therapy (Table 2). Eighty ﬁ  ve percent of the 
surveyed physicians indicated that their self assessment of 
risk reduction in PAD was average to below average.
Attitude towards routine patients counseling with regard 
to the importance of risk factor control was suboptimal Vascular Health and Risk Management 2007:3(6) 1021
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(Table 3). Apart from routine initiation of antiplatelets 
therapy (86.3%), the attitude towards routine initiation and/or 
modiﬁ  cation of other risk reduction therapy was very poor 
especially for initiating ACE inhibitors (17.7%). The high-
est threshold for initiating different risk reduction therapies 
was observed among general internist compared to other 
specialists, however, it was only statistically signiﬁ  cant for 
initiating statin therapy (p = 0.025). On the other hand, car-
diologists appeared to have the lowest threshold in initiating 
these therapies; however, it was not statistically signiﬁ  cant 
for any therapy (Table 3). Two third of participants evaluate 
less than half of their PAD patients for vascular risk factors 
(Table 3).
Barriers for delivering risk reduction 
therapy
The barriers for not receiving adequate risk reduction therapy 
with the participants’ responses are shown in Table 4.
Discussion
Patients with PAD generally have widespread arterial 
disease and therefore are at a signiﬁ  cantly increased risk 
of stroke, myocardial infarction, and cardiovascular death 
(The TASC Working Group 2001). Coronary artery disease 
(CAD) is the most common cause of death in patients with 
PAD and accounts for 40%–60% of deaths. Stroke accounts 
for 10%–20% of deaths. Only 20% to 30% of patients with 
PAD die of non-cardiovascular causes (The TASC Work-
ing Group 2001). Patients with PAD have a 6 fold increased 
risk of cardiovascular disease mortality compared to patients 
without PAD (Criqui et al 1992). Therefore, intensive risk 
reduction therapy is critical in these patients to reduce the 
adverse cardiovascular outcomes. Risk reduction pharmaco-
therapy (antiplatelets, statins, and ACE inhibitors) are proven 
therapy in reducing the risk of cardiovascular mortality 
and morbidity in PAD patients in large scale randomized 
clinical trials (Yusuf et al 2000; Antithrombotic Trialists’ 
Collaboration 2002; Heart Protection Collaborative Group 
2002). On the other hand, although there are no randomized 
clinical trials to prove the role of smoking cessation and 
blood sugar control in reducing the adverse cardiovascular 
outcomes in patients with atherosclerosis; large observational 
studies showed their effect to do so (Lu and Creager 2004; 
Stratton et al 2004).
The compelling evidence from the literature has led 
several expert panels to recommend atherosclerotic risk 
reduction therapy use in all patients with PAD (Expert Panel 
on Detection 2001; Smith et al 2001, 2006; American Diabe-
tes Association 2003; Chobanian et al 2003). Furthermore, 
with the increasing recognition of the disease burden in 
patients with PAD, separate guidelines have been published 
to encourage the use of risk reduction therapies (Abramson 
et al 2005; Hirsch et al 2006).
Although there is strong evidence supporting the impor-
tance of using risk reduction therapy in patients with PAD, 
in this study we have shown that despite the majority of sur-
veyed physicians evaluate and counsel patients with PAD for 
their risk factors, knowledge and action remain suboptimal, 
and clear gaps have been identiﬁ  ed. Majority of surveyed 
physicians rated their knowledge about risk reduction as 
average or above average; however, there is deﬁ  ciency in 
the knowledge of the recommended target levels of blood 
pressure and LDL-cholesterol levels. In addition, minority 
of the participants knew that ACE inhibitor can be used in 
PAD patients irrespective to the blood pressure status for 
reducing atherosclerotic complications and cardiovascular 
death. Furthermore, there was also deﬁ  ciency in initiating 
risk reduction therapy especially for ACE inhibitors and 
anti-smoking therapies. The action gap was most prominent 
among general internists compared to other specialties.
Our ﬁ  ndings could be explained by the absence of national 
or locally adapted guidelines in managing patients with PAD 
Table 1 Characteristics of physicians who completed the survey by specialty (N = 51)
    Family physicians  General internists  Cardiologists  Vascular surgeons  All
   (N = 20)  (N = 17) (N = 8)  (N = 6) (N = 51)
Response  rate,%  66.7  53.1 53.3  85.0 60.7
Mean age, y, +/− SD  43.2 +/− 5.2  39.7 +/− 7.2  38.8+/− 6.5  39.5+/−4.2 40.8+/–5.3
Male gender,%   55.0  64.7  100  100   70.6
Board-certiﬁ   ed,%  60.0  58.8 87.5  50.0 66.7
Years in Practice         
   5  years,%  10.0  29.4 62.5  66.8 31.4
  5–10 years,%   25.0  29.4  12.5  16.6  23.5
   10  years,%  65.0  41.2 25.0  16.6 45.0Vascular Health and Risk Management 2007:3(6) 1022
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and the reluctance of physicians to apply CAD guidelines 
to the PAD patient population even though the risks are 
similar, if not higher (Criqui et al 1992). Furthermore, the 
suboptimal use of ACE inhibitors could be explained by the 
fact that the evidence supporting the use of ACE inhibitors 
in patients with PAD to reduce the risk of adverse cardio-
vascular events is not a level A evidence and also dependent 
on the presence of symptoms (class IIa recommendation for 
symptomatic patients with PAD and Class IIb recommenda-
tion for asymptomatic patients) (Hirsch et al 2006).
Knowledge and action gaps in managing risk factors 
in patients with PAD also have been shown among physi-
cians in the United Kingdom, the United States and Canada 
(McDermott et al 2002; Mukherjee et al 2002; Cassar et al 
2003; Al Omran et al 2006). Cassar et al (2003) showed that 
over a quarter of the UK vascular surgeons would not screen 
for diabetes or measure blood pressure in patients with PAD 
and only 34% of them would treat claudicants if the choles-
terol was greater than 5.5 mmol/l. McDeermott et al (2002) 
showed that only 45.5% of the internal medicine physicians 
(IMP) prescribe antiplatelets to patients with PAD compared 
to 52.5% of the vascular surgeons, and only 16.8% of the 
vascular surgeons knew the large effect of cholesterol lower-
ing on the risk of future cardiovascular events in patients with 
PAD compared to 43.6% of the IMP. Furthermore, even in 
cardiologists who were surveyed there was knowledge and 
action gaps in dealing with atherosclerotic risk. Al-Omran 
et al (2006) showed that the utilization of risk reduction 
pharmacotherapy and the knowledge of the recommended 
target levels of blood glucose, blood pressure and LDL-
cholesterol levels in patients with PAD among Canadian 
vascular surgeons were suboptimal. Furthermore, Mukherjee 
et al showed a suboptimal use of lifestyle modiﬁ  cations such 
as smoking cessation, exercise, weight reduction and diet for 
lipid control, and the use of evidence-based therapy such as 
antiplatelets therapy, ACE-inhibitors, beta-blockers, and 
statins in patients undergoing peripheral vascular interven-
tions for PAD at hospital discharge and at 6 months follow-up 
(Mukherjee et al 2002).
The knowledge and action gaps in managing risk factors 
in patients with PAD from the previously published studies 
(McDermott et al 2002; Cassar et al 2003; Al Omran et al 
2006) along with our data add support to the available litera-
ture documenting inequities in use of risk reduction therapies 
for patients with PAD in comparison to patients with CAD 
(Hirsch et al 2004). Furthermore, this data can be useful in 
supporting a call to action for PAD management and public 
awareness (Hirsch et al 2004).
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In the evaluation of these results, certain limitations merit 
emphasis. The small number of the participants included in this 
survey. It is also important to stress that this survey reﬂ  ects the 
practice of physicians in a single teaching institute, and may not 
be generalizable to other hospitals. Also, since the data represent 
self-reported perceptions of knowledge they may underestimate 
the true gap. In addition, the survey form did not differentiate 
between symptomatic and asymptomatic PAD with regard to the 
use of ACE inhibitors as a risk reduction therapy.
In conclusion, the perceptions towards risk reduction in 
PAD identify glaring knowledge and action gaps, despite a 
considerable effort to evaluate and counsel patients for their risk 
factors. Given the heightened risk of cardiovascular adverse 
outcomes in patients with PAD, these data have important and 
immediate implications. If the current practice continues, the 
observed knowledge and action gaps are expected to persist. 
These ﬁ  ndings may be useful for guiding targeted interventions 
such as locally adapted clinical practice guidelines in managing 
patients with PAD, self audit of practice, focused continuing 
medical education programs, the inclusion of risk reduction 
pharmacotherapy as a plenary topic at scientiﬁ  c meetings, 
and other educational outreach programs that aim to bring 
physicians’ practice into agreement with current guidelines 
for cardiovascular risk reduction.
Note
Presented in part at the 7th International Congress of the 
Asian Society for Vascular Surgery, Kuala Lumpur, Malay-
sia, August 2006.
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Appendix
The survey questionnaire
Please encircle the chosen answer
What is your age?  ------- years
What is your gender ?  Male  Female
What’s your speciality? General practitioner  Internist  Cardiologist  Vascular surgeon
Are you board certiﬁ  ed?  Yes  No
Hospital name and city?  ………………./……………….
Nationality? ………………………………...
How many are you in practice in your speciality?   5 years  5–10 years   10 years
What do you perceive as being the main cause  a) Limb loss
of morbidity and mortality in patients with PAD?  b) Perioperative complications
    c) Cardiovascular events, including, MI,Stroke and
   Cardiovascular  outcomes
What proportion of your patients with PAD have  a) None
their vascular risk factors evaluated systematically  b)  50%
by your self?  c)  50%
Please rate your knowledge of risk reduction  a) Average
therapies in PAD  b) Below average
   c)  Above  average
  i) Diabetes mellitus
If PAD patient is not diabetic, do you measure  Yes  No
Random and/or fasting blood sugar as a screening
tool?
What are the current recommendations with respect to  a) Unsure
glucose control in patients with diabetes?  b) HbA1c   7% in all patients, with an effort to
   achieve  HbA1c    6% ideally, if possible
    c) Fasting blood glucose of   10mmol/L
Do you routinely counsel diabetic patients  Yes  No
regarding the importance of diabetes control?
  ii) Cigarette smoking
Do you routinely ask these patients about smoking history?  Yes  No
Do you routinely advise these patients to stop smoking?  Yes  No
Do you routinely recommend nicotine replacement  Yes  No
therapy and/or other proven cessation intervention
in these patients?
Do you refer these patients to smoking cessation program?  Yes  No
  iii) Lipid control
Do you routinely measure lipid values?  Yes  No
What are the current LDL-cholesterol target  a) Unsure
level in patients with PAD?  b) less than 3.5 mmol/L
    c) less than 4.5 mmol/L
    d) less than 2.5 mmol/L
    e) less than 1.7 mmol/LVascular Health and Risk Management 2007:3(6) 1027
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Do you routinely counsel these patients regarding
the importance of LDL-cholesterol reduction in   Yes  No
PAD to achieve LDL-target level?
Do you routinely prescribe or modify statin  a) No
therapy in patients with PAD?  b) In few patients
    c) In majority of patients
  iv) Hypertension control
Do you routinely measure patient’s blood pressure?  Yes  No
What is the current blood pressure target  a) Unsure
for patients with PAD?  b) Less than 140/80 mmHg
    c) Less than 125/75 mmHg
    d) Less than 130/85 mmHg
    e) Lowest achievable
Do you routinely counsel patients regarding   Yes  No
the importance of blood pressure control?
Do you routinely initiate or modify antihypertensive  a) No
therapy in patients with PAD?  b) In few patients
    c) In majority of patients
 v)  Antiplatelets  therapy
Do you routinely initiate aspirin in patients with PAD?   Yes  No
If aspirin is contraindicated or intolerable, do you   Yes  No
prescribe other antiplatelets agents? If yes indicate
the antiplatelets therapy you prescribe  (………………………….)
  vi) Angiotensin converting enzyme inhibitor
   (ACE-I)  therapy
Should all patients with PAD receive an ACE inhibitor  a) If patients with PAD have normal BP, ACE-I therapy
irrespective of their blood pressure?  is not indicated
    b) ACE-I therapy should be initiated in every patient
    with PAD, irrespective of their BP
    c) I am unclear what the exact recommendations regarding
    ACE-I in PAD are at the present time
Do you routinely initiate ACE inhibitor therapy in  a) No
patients with PAD?  b) In few patients
    c) In majority of patients
  vii) Management barriers in patients with PAD
What is the most important barrier to your patients  a) Lack of knowledge of treating physician about PAD
with PAD not receiving risk reduction therapies,  b) Lack of PAD management guidelines
and reaching targets for vascular protection?  c) Lack of continuing education in the importance of
(Chose one answer)  risk reduction approaches in global cardiovascular
   protection
    d) Absence of vascular medicine speciality in Saudi
    e) All of the above